You are here

Publications

Found 188 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Bockman MR, Kalinda AS, Petrelli R, De la Mora-Rey T, Tiwari D, Liu F, Dawadi S, Nandakumar M, Rhee KY, Schnappinger D et al..  2015.  Targeting Mycobacterium tuberculosis Biotin Protein Ligase (MtBPL) with Nucleoside-Based Bisubstrate Adenylation Inhibitors.. J Med Chem. 58(18):7349-7369.
Tiwari D, Park SWoong, Essawy MM, Dawadi S, Mason A, Nandakumar M, Zimmerman M, Mina M, Ho HPin, Engelhart CA et al..  2018.  Targeting protein biotinylation enhances tuberculosis chemotherapy.. Sci Transl Med. 10(438)
Trevejo JM, Marino MW, Philpott N, Josien R, Richards EC, Elkon KB, Falck-Pedersen E.  2001.  TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection.. Proc Natl Acad Sci U S A. 98(21):12162-7.
Philpott NJ, Gomos J, Falck-Pedersen E.  2004.  Transgene expression after rep-mediated site-specific integration into chromosome 19.. Hum Gene Ther. 15(1):47-61.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YKenneth, Depetris R, Marozsan AJ, Sanders RW et al..  2011.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.. Proc Natl Acad Sci U S A. 108(28):11440-5.
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al..  1998.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.. Immunity. 9(1):25-34.
Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF.  2021.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.. J Exp Med. 218(2)
Byrnes AA, Ma X, Cuomo P, Park K, Wahl L, Wolf SF, Zhou H, Trinchieri G, Karp CL.  2001.  Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity.. Eur J Immunol. 31(7):2026-34.